Phase 3 Parkinson's Disease Trial, Recruiting NCT04706910 Sponsor: University of Alberta Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 3 Parkinson's Disease Trial, Recruiting

NCT04706910
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children under 18 years old who have been diagnosed with congenital hyperinsulinism (a condition where the body produces too much insulin).
  • Children under 18 years old who have been diagnosed with neuroblastoma (a type of cancer that develops from nerve cells).
  • Children under 18 years old, or adults aged 18 and over, with a known or suspected neuroendocrine tumour (a type of tumour that can develop in hormone-producing cells).
  • Adults aged 18 and over with a known or suspected diagnosis of Parkinson's disease or Lewy body dementia.
  • Children under 18 years old, or adults aged 18 and over, who have been diagnosed with a brain tumour.

Who may not be able to join:

  • People for whom consent cannot be obtained.
  • People who weigh more than 225 kg, due to the weight limit of the scanning equipment used in the trial.
  • Adults who are unable to lie still and flat for 20 to 30 minutes during the scan.
  • Children under 13 years old who are unable to lie still and flat for 20 to 30 minutes, and for whom sedation is not considered medically safe by a specialist children's anaesthetist.
  • People who do not have a usable vein for an intravenous line (a small tube placed into a vein).
  • People who have previously had their gallbladder surgically removed — this exclusion applies only to a specific part of the study involving abdominal scans (confirm with trial site).
  • People who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jonathan Abele, MD, University of Alberta

Phone: 1-780-407-6907

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
20 January 2021
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Minimum lesion detectibility (size); Assessment of bladder activity; Assessment of bladder activity artifact; Minimum lesion detectability (SUV)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov